Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation

被引:97
作者
Perreault, Sylvie [1 ]
de Denus, Simon [1 ,2 ]
White-Guay, Brian [3 ]
Cote, Robert [4 ]
Schnitzer, Mireille E. [1 ]
Dube, Marie-Pierre [3 ,4 ]
Dorais, Marc [5 ]
Tardif, Jean-Claude [2 ,3 ]
机构
[1] Univ Montreal, Fac Pharm, Montreal, PQ, Canada
[2] Montreal Heart Inst, Montreal, PQ, Canada
[3] Univ Montreal, Fac Med, Montreal, PQ, Canada
[4] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada
[5] StatSciences Inc, Notre Dame De Lile Perro, PQ, Canada
来源
PHARMACOTHERAPY | 2020年 / 40卷 / 01期
关键词
anticoagulant; atrial fibrillation; trend of use; pattern of use; ANTITHROMBOTIC THERAPY; RISK STRATIFICATION; COMORBIDITY INDEX; WARFARIN; STROKE; POLYMORPHISMS; ASSOCIATION; VALIDATION; HEMORRHAGE; PREVENTION;
D O I
10.1002/phar.2350
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose Data on oral anticoagulant (OAC) uptake and pattern of use are limited. Real-life data in patients with atrial fibrillation (AF) are important for understanding patient exposure. A cohort study of new OAC users was built to assess trends of drug use from 2011 to 2017, persistence rate, switching rate, adherence level, and predictors of adherence. Methods We built a cohort using the Regie d'Assurance Maladie du Quebec (RAMQ) and Med-Echo administrative databases of new adult OAC users within 1 year following hospitalization with a diagnosis of AF. New users of OAC were defined as having no OAC claims in the year before cohort entry. We assessed trends of OAC use; persistence rate, defined as a gap between refills of no longer than two times the duration of the previous prescriptions; and adherence level, defined as the proportion of days covered (PDC) over a 1-year period following initiation. Predictors of nonadherence (PDC less than 80%) were analyzed using logistic regression models. Results The cohort consisted of 33,311 incident OAC users. Of total OAC claims, the proportions of warfarin claims decreased from 77.9% in 2011 to 12.7% in 2017, with direct oral anticoagulants (DOACs) accounting for 87.3% of claims, of which apixaban and rivaroxaban accounted for 60.1% and 23.4%, respectively, by the end of 2017. One year after OAC initiation, persistence rates ranged from 53% with warfarin to 77% with a high dose of apixaban. Approximately 75% of incident OAC users were considered "adherent" (PDC 80% or more), with a mean PDC of 95.6-98.1%, compared with "nonadherent," with a mean PDC varying between 43.1% and 50.7%. Older age, female sex, higher CHA(2)DS(2)-VASc score (to predict thromboembolic risk in AF), prior stroke, and treatment with chronic cardiovascular disease drugs were associated with high adherence levels. Conclusion The clinical uptake of DOACs increased over time, accounting for 87.3% of prescriptions in 2017. In our study, 25% of new OAC users presented a low adherence level. Adherence to OACs remains a significant challenge in patients with AF.
引用
收藏
页码:40 / 54
页数:15
相关论文
共 46 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   Safe and Effective Anticoagulation: What Does Drug Concentration Add? [J].
Alexander, Karen P. ;
Alexander, John H. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 (09) :1772-1773
[3]   Direct oral anticoagulants: a review of common medication errors [J].
Barr, Drakeria ;
Epps, Quovadis J. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (01) :146-154
[4]   Adherence: An Important Metric to Assess Pharmacist Value in Quality Care [J].
Campbell, Patrick J. .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10) :1044-1045
[5]   Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the US Adult Population [J].
Colilla, Susan ;
Crow, Ann ;
Petkun, William ;
Singer, Daniel E. ;
Simon, Teresa ;
Liu, Xianchen .
AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (08) :1142-1147
[6]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[7]   Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications [J].
Crivera, Concetta ;
Nelson, Winnie W. ;
Bookhart, Brahim ;
Martin, Silas ;
Germain, Guillaume ;
Laliberte, Francois ;
Schein, Jeffrey ;
Lefebvre, Patrick .
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (10) :1889-1895
[8]   Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation Report of the Guideline Development Subcommittee of the American Academy of Neurology [J].
Culebras, Antonio ;
Messe, Steven R. ;
Chaturvedi, Seemant ;
Kase, Carlos S. ;
Gronseth, Gary .
NEUROLOGY, 2014, 82 (08) :716-724
[9]   Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation-Quality and Cost Implications [J].
Desai, Nihar R. ;
Krumme, Alexis A. ;
Schneeweiss, Sebastian ;
Shrank, William H. ;
Brill, Gregory ;
Pezalla, Edmund J. ;
Spettell, Claire M. ;
Brennan, Troyen A. ;
Matlin, Olga S. ;
Avorn, Jerry ;
Choudhry, Niteesh K. .
AMERICAN JOURNAL OF MEDICINE, 2014, 127 (11) :1075-+
[10]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619